This HTML5 document contains 201 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n29http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/company/
n5http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/national-drug-code-directory/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/mixture/
n21http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/patent/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00373/identifier/pdb/
n11http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00373
rdf:type
n3:Drug
n3:description
A beta-adrenergic antagonist similar in action to propranolol. The levo-isomer is the more active. Timolol has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of migraine disorders and tremor. [PubChem]
n3:dosage
n19:271B633A-363D-11E5-9242-09173F13E4C5 n19:271B633B-363D-11E5-9242-09173F13E4C5 n19:271B633C-363D-11E5-9242-09173F13E4C5 n19:271B6336-363D-11E5-9242-09173F13E4C5 n19:271B6337-363D-11E5-9242-09173F13E4C5 n19:271B6338-363D-11E5-9242-09173F13E4C5 n19:271B6339-363D-11E5-9242-09173F13E4C5 n19:271B6333-363D-11E5-9242-09173F13E4C5 n19:271B6334-363D-11E5-9242-09173F13E4C5 n19:271B6335-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.inchem.org/documents/pims/pharm/timolol.htm
n3:group
approved
n3:halfLife
2.5-5 hours
n3:indication
In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its opthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
n3:manufacturer
n16:271B62E5-363D-11E5-9242-09173F13E4C5 n16:271B62E6-363D-11E5-9242-09173F13E4C5 n16:271B62E3-363D-11E5-9242-09173F13E4C5 n16:271B62E4-363D-11E5-9242-09173F13E4C5 n16:271B62F1-363D-11E5-9242-09173F13E4C5 n16:271B62F2-363D-11E5-9242-09173F13E4C5 n16:271B62EF-363D-11E5-9242-09173F13E4C5 n16:271B62F0-363D-11E5-9242-09173F13E4C5 n16:271B62F5-363D-11E5-9242-09173F13E4C5 n16:271B62F6-363D-11E5-9242-09173F13E4C5 n16:271B62F3-363D-11E5-9242-09173F13E4C5 n16:271B62F4-363D-11E5-9242-09173F13E4C5 n16:271B62E9-363D-11E5-9242-09173F13E4C5 n16:271B62EA-363D-11E5-9242-09173F13E4C5 n16:271B62E7-363D-11E5-9242-09173F13E4C5 n16:271B62E8-363D-11E5-9242-09173F13E4C5 n16:271B62ED-363D-11E5-9242-09173F13E4C5 n16:271B62EE-363D-11E5-9242-09173F13E4C5 n16:271B62EB-363D-11E5-9242-09173F13E4C5 n16:271B62EC-363D-11E5-9242-09173F13E4C5 n16:271B62F7-363D-11E5-9242-09173F13E4C5 n16:271B62F8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00373 n21:DB00373
dcterms:title
Timolol
adms:identifier
n7:Timolol n22:39465 n24:C07141 n25:68669-522-05 n26:DB00373 n27:TIM n28:PA451690
n3:mechanismOfAction
Like propranolol and nadolol, timolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta(2)-blockade results in an increase in peripheral vascular resistance. The exact mechanism whereby timolol reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor.
n3:packager
n16:271B62CD-363D-11E5-9242-09173F13E4C5 n16:271B62CE-363D-11E5-9242-09173F13E4C5 n16:271B62CB-363D-11E5-9242-09173F13E4C5 n16:271B62CC-363D-11E5-9242-09173F13E4C5 n16:271B62C9-363D-11E5-9242-09173F13E4C5 n16:271B62CA-363D-11E5-9242-09173F13E4C5 n16:271B62C7-363D-11E5-9242-09173F13E4C5 n16:271B62C8-363D-11E5-9242-09173F13E4C5 n16:271B62D5-363D-11E5-9242-09173F13E4C5 n16:271B62D6-363D-11E5-9242-09173F13E4C5 n16:271B62D3-363D-11E5-9242-09173F13E4C5 n16:271B62D4-363D-11E5-9242-09173F13E4C5 n16:271B62D1-363D-11E5-9242-09173F13E4C5 n16:271B62D2-363D-11E5-9242-09173F13E4C5 n16:271B62CF-363D-11E5-9242-09173F13E4C5 n16:271B62D0-363D-11E5-9242-09173F13E4C5 n16:271B62C5-363D-11E5-9242-09173F13E4C5 n16:271B62C6-363D-11E5-9242-09173F13E4C5 n16:271B62C3-363D-11E5-9242-09173F13E4C5 n16:271B62C4-363D-11E5-9242-09173F13E4C5 n16:271B62C2-363D-11E5-9242-09173F13E4C5 n16:271B62DD-363D-11E5-9242-09173F13E4C5 n16:271B62DE-363D-11E5-9242-09173F13E4C5 n16:271B62DB-363D-11E5-9242-09173F13E4C5 n16:271B62DC-363D-11E5-9242-09173F13E4C5 n16:271B62D9-363D-11E5-9242-09173F13E4C5 n16:271B62DA-363D-11E5-9242-09173F13E4C5 n16:271B62D7-363D-11E5-9242-09173F13E4C5 n16:271B62D8-363D-11E5-9242-09173F13E4C5 n16:271B62E1-363D-11E5-9242-09173F13E4C5 n16:271B62E2-363D-11E5-9242-09173F13E4C5 n16:271B62DF-363D-11E5-9242-09173F13E4C5 n16:271B62E0-363D-11E5-9242-09173F13E4C5
n3:patent
n20:5231095 n20:6174524
n3:routeOfElimination
Timolol and its metabolites are primarily excreted in the urine.
n3:synonym
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol Timololum Timololo Timolol
n3:toxicity
LD<sub>50</sub>=1190 mg/kg (oral, mice), LD<sub>50</sub>=900 mg/kg (oral, rat). Symptoms of overdose include drowsiness, vertigo, headache, and atriventricular block.
n14:hasAHFSCode
n17:24-24-00 n17:52-92-00
n3:mixture
n18:271B62C1-363D-11E5-9242-09173F13E4C5 n18:271B62BB-363D-11E5-9242-09173F13E4C5 n18:271B62BC-363D-11E5-9242-09173F13E4C5 n18:271B62BA-363D-11E5-9242-09173F13E4C5 n18:271B62BF-363D-11E5-9242-09173F13E4C5 n18:271B62C0-363D-11E5-9242-09173F13E4C5 n18:271B62BD-363D-11E5-9242-09173F13E4C5 n18:271B62BE-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
~10%
n3:salt
n3:synthesisReference
Markku Per alampi, "S-timolol hemihydrate composition and method of preparation therefor." U.S. Patent US5574035, issued October, 1986.
n4:hasConcept
n5:M0021546
foaf:page
n11:timolol-drops.html n29:timololgfs.htm
n3:IUPAC-Name
n8:271B6341-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B6347-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B6346-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B6343-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B6344-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B6345-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B6357-363D-11E5-9242-09173F13E4C5 n8:271B633F-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B6359-363D-11E5-9242-09173F13E4C5 n8:271B6340-363D-11E5-9242-09173F13E4C5 n8:271B633D-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B633E-363D-11E5-9242-09173F13E4C5
n3:pKa
n8:271B635B-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:C07AA06 n15:S01ED01
n3:H-Bond-Acceptor-Count
n8:271B634D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B634E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B6348-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B6349-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B634B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B634A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B634C-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is about 60%
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n8:271B635A-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
26839-75-8
n3:category
n3:containedIn
n9:271B6332-363D-11E5-9242-09173F13E4C5 n9:271B6330-363D-11E5-9242-09173F13E4C5 n9:271B6331-363D-11E5-9242-09173F13E4C5 n9:271B6326-363D-11E5-9242-09173F13E4C5 n9:271B6327-363D-11E5-9242-09173F13E4C5 n9:271B6324-363D-11E5-9242-09173F13E4C5 n9:271B6325-363D-11E5-9242-09173F13E4C5 n9:271B6322-363D-11E5-9242-09173F13E4C5 n9:271B6323-363D-11E5-9242-09173F13E4C5 n9:271B6320-363D-11E5-9242-09173F13E4C5 n9:271B6321-363D-11E5-9242-09173F13E4C5 n9:271B632E-363D-11E5-9242-09173F13E4C5 n9:271B632F-363D-11E5-9242-09173F13E4C5 n9:271B632C-363D-11E5-9242-09173F13E4C5 n9:271B632D-363D-11E5-9242-09173F13E4C5 n9:271B632A-363D-11E5-9242-09173F13E4C5 n9:271B632B-363D-11E5-9242-09173F13E4C5 n9:271B6328-363D-11E5-9242-09173F13E4C5 n9:271B6329-363D-11E5-9242-09173F13E4C5 n9:271B6316-363D-11E5-9242-09173F13E4C5 n9:271B6317-363D-11E5-9242-09173F13E4C5 n9:271B6314-363D-11E5-9242-09173F13E4C5 n9:271B6315-363D-11E5-9242-09173F13E4C5 n9:271B6312-363D-11E5-9242-09173F13E4C5 n9:271B6313-363D-11E5-9242-09173F13E4C5 n9:271B6310-363D-11E5-9242-09173F13E4C5 n9:271B6311-363D-11E5-9242-09173F13E4C5 n9:271B631E-363D-11E5-9242-09173F13E4C5 n9:271B631F-363D-11E5-9242-09173F13E4C5 n9:271B631C-363D-11E5-9242-09173F13E4C5 n9:271B631D-363D-11E5-9242-09173F13E4C5 n9:271B631A-363D-11E5-9242-09173F13E4C5 n9:271B631B-363D-11E5-9242-09173F13E4C5 n9:271B6318-363D-11E5-9242-09173F13E4C5 n9:271B6319-363D-11E5-9242-09173F13E4C5 n9:271B6306-363D-11E5-9242-09173F13E4C5 n9:271B6307-363D-11E5-9242-09173F13E4C5 n9:271B6304-363D-11E5-9242-09173F13E4C5 n9:271B6305-363D-11E5-9242-09173F13E4C5 n9:271B6302-363D-11E5-9242-09173F13E4C5 n9:271B6303-363D-11E5-9242-09173F13E4C5 n9:271B6300-363D-11E5-9242-09173F13E4C5 n9:271B6301-363D-11E5-9242-09173F13E4C5 n9:271B630E-363D-11E5-9242-09173F13E4C5 n9:271B630F-363D-11E5-9242-09173F13E4C5 n9:271B630C-363D-11E5-9242-09173F13E4C5 n9:271B630D-363D-11E5-9242-09173F13E4C5 n9:271B630A-363D-11E5-9242-09173F13E4C5 n9:271B630B-363D-11E5-9242-09173F13E4C5 n9:271B6308-363D-11E5-9242-09173F13E4C5 n9:271B6309-363D-11E5-9242-09173F13E4C5 n9:271B62FE-363D-11E5-9242-09173F13E4C5 n9:271B62FF-363D-11E5-9242-09173F13E4C5 n9:271B62FC-363D-11E5-9242-09173F13E4C5 n9:271B62FD-363D-11E5-9242-09173F13E4C5 n9:271B62FA-363D-11E5-9242-09173F13E4C5 n9:271B62FB-363D-11E5-9242-09173F13E4C5 n9:271B62F9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B6353-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B6355-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B6356-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B6358-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B6352-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B6351-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B6354-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B6342-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B634F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B6350-363D-11E5-9242-09173F13E4C5